Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 2:40 PM ET

Pharmaceuticals

Company Overview of Protein Sciences Corporation

Company Overview

Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...

1000 Research Parkway

Meriden, CT 06450

United States

Founded in 1983

Phone:

203-686-0800

Fax:

203-686-0268

Key Executives for Protein Sciences Corporation

Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Senior Vice President of Manufacturing Operations
Chief Medical Officer
Senior Vice President of Quality
Compensation as of Fiscal Year 2015.

Protein Sciences Corporation Key Developments

Protein Sciences Corporation Receives Approval from FDA for 2015/16 Formulation of Flublok Influenza Vaccine

Protein Sciences Corporation announced that the FDA has approved the composition of Flublok influenza vaccine for the 2015/16 flu season. Every year, influenza vaccine manufacturers must receive approval from the FDA for changes they make to their vaccines so that the vaccines protect against the new strains of flu that are predicted to circulate next flu season. This year, there are two strain changes. Traditional (egg-based) vaccine manufacturers may experience vaccine production delays during years when there are two or more new strains of flu as traditional manufacturing technology is slow; this was the case in the spring for the Southern Hemisphere with influenza vaccine delivery delays of over a month. In contrast, the technology used to make Flublok is fast. This approval enables to deliver Flublok to distributors and retailers in mid-August. Early availability of Flublok is especially important for those that rely on Flublok's unique properties for protection from the flu; namely, that the vaccine is highly pure (including being egg-, antibiotic-, latex-, gelatin-, gluten- and preservative-free) and contains three times more active ingredients than traditional flu vaccines. A recent clinical study of the quadrivalent version of Flublok in approximately 9,000 adults 50 years and older showed that Flublok recipients were 31% less likely to develop laboratory confirmed influenza than the people that received a traditional egg-based quadrivalent vaccine.

Protein Sciences New York Facility Receives FDA Licensure to Manufacture Flublok®

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration (FDA) licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok® influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology. The approval of its Pearl River facility accelerates the growth of Protein Sciences and Flublok.

Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation Enter into Agreement to Evaluate Sourcing Flublok® from Japan

Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation announced that they have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan. The drug substances would be manufactured at the Gifu (Japan) Plant of UNIGEN, a subsidiary of UMN Pharma in which IHI holds 50% of the common shares. UNIGEN manufactures Flublok for UMN Pharma at the 21,000L scale - ten times the scale the vaccine is manufactured in the United States. The Gifu plant has two 21,000L bioreactors and has the capacity to add six additional bioreactors. UMN holds a license from Protein Sciences for Flublok for the territories of Japan, China, Korea, Hong Kong, Taiwan and Singapore. UMN is partnered with Astellas to market Flublok in Japan.

Similar Private Companies By Industry

Company Name Region
Rempex Pharmaceuticals, Inc. United States
Altheus Therapeutics, Inc. United States
Phytoceutical, Inc. United States
Anchen Pharmaceuticals, Inc. United States
Voyager Health Technologies Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 18, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Protein Sciences Corporation, please visit www.proteinsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.